![]() |
市場調查報告書
商品編碼
1324364
到 2030 年模組化實驗室自動化市場預測:按設備和軟體、用途和地區進行的全球分析Modular Laboratory Automation Market Forecasts to 2030 - Global Analysis By Equipment and Software, Application and By Geography |
根據 Stratistics MRC 的數據,2023 年全球模組化實驗室自動化市場規模為 38.9 億美元,預計在預測期內將以 8.1% 的年複合成長率成長,到 2030 年達到 67.1 億美元。
模組化實驗室自動化是一種常用於藥物研發、診斷、基因組學等領域的實驗室自動化流程。任何能夠提高實驗室生產力和效率同時幾乎不需要人工干涉的設備、軟體或設備都被稱為“實驗室自動化”。機器人、輸送機、軟體和其他設備都是自動化的一部分。
實驗室始終需要更快、更有效的程序,尤其是在製藥、生物技術和臨床研究行業。模組化實驗室自動化提供的自動化單調且耗時的任務的能力將在預測期內顯著提高該市場的吞吐量和整體效率。
實施模組化實驗室自動化系統時,設備、軟體和整合的初始投資可能很高。對於小型實驗室或預算有限的實驗室來說,初始成本可能是一個主要障礙。這些要素限制了市場的擴張。
由於機器人、感測器技術和整合能力方面的技術進步,模組化實驗室自動化系統現在更具適應性、可靠性和經濟性。由於這些發展,各種實驗室過程中自動化的應用範圍正在擴大。此外,自動化系統可以幫助提高資料可追溯性和準確性,提高合規性和審核準備度。
實驗室行業的自動化協議和介面通常沒有標準化。因此,各種自動化組件之間可能會出現兼容性問題,阻礙自動化系統的順利整合。此外,兼容性問題和客製化解決方案的需求可能會增加實施時間和成本。
COVID-19 大流行加速了醫學研究和開發,同時給製藥公司和臨床實驗室帶來了額外的壓力。由於人們對酶標儀、自動液體處理和機器人技術的興趣日益濃厚,確保實現 TAT 降低非常重要。與此同時,流行病減少了自動化和技術方面的支出,降低了醫院和衛生系統的收入和利潤率。這將影響模組化實驗室自動化的未來市場。
在預測期內,自動液體處理機市場預計將是最大的。液體處理機經常用於化學和生物化學實驗室。在實驗室中,自動液體處理機器人協助分配樣品和其他液體。自動液體處理機可縮短週期時間並提高精度。此外,液體處理器可以容納低至納升的各種體積,展示了其在分配操作中的價值。
預計臨床診斷領域在預測期內將出現良好的成長。模組化實驗室自動化廣泛應用於臨床診斷,因為它可以最佳化實驗室工作流程、提高生產力、提高準確性並減少人為錯誤的機會。此外,模組化自動化可用於自動化各種檢測和臨床化學測試,使實驗室能夠快速處理大量測試,而無需用戶參與。
由於所有最終用戶領域廣泛採用最尖端科技,預計北美將主導模組化實驗室自動化市場。預計該市場將受到對尖端基因組學、蛋白質組學和表觀遺傳學研究的投資、對環境問題日益關注以及全球最大的製藥和生物技術公司和學術機構的集中推動。
亞太地區對實驗室自動化解決方案的需求預計將增加,這主要是由於製藥行業的爆炸性成長。持續的人口和經濟趨勢、新的醫療改革以及政府五年計劃中概述的政策預計將支持市場擴張。由於市場的快速擴張,實驗室自動化解決方案供應商有了擴大足跡的新機會。
According to Stratistics MRC, the Global Modular Laboratory Automation Market is accounted for $3.89 billion in 2023 and is expected to reach $6.71 billion by 2030 growing at a CAGR of 8.1% during the forecast period. Modular Lab Automation is a type of laboratory automation process frequently used in drug discovery, diagnostics, genomics, etc. Any device, piece of software, or piece of equipment that requires little to no human interaction while increasing lab productivity and efficiency is referred to as "laboratory automation." Robots, conveyors, software, and other devices are all part of automation.
Faster and more effective procedures are constantly needed in laboratories, particularly those in the pharmaceutical, biotechnology, and clinical research industries. The ability to automate monotonous and time-consuming tasks is provided by modular laboratory automation, significantly boosting throughput and overall effectiveness of this market during the forecast period.
Equipment, software, and integration are frequently expensive up front when implementing modular laboratory automation systems. For smaller labs or those with tighter budgets, the initial cost can be a major barrier. Such factors limit market expansion.
Modular laboratory automation systems are now more adaptable, dependable, and economical thanks to technological advancements in robotics, sensor technologies, and integration capabilities. The range of applications for automation in different laboratory processes has increased as a result of these developments. Moreover, automation systems can also help increase data traceability and accuracy, boosting compliance and audit readiness.
Automation protocols and interfaces are frequently not standardised in the laboratory industry. As a result, there may be compatibility problems between various automation components, which could obstruct the smooth integration of automation systems. Moreover, compatibility problems and the need for customised solutions can also increase the time and cost of implementation.
The COVID-19 pandemic has sped up medical research and development while putting more pressure on pharmaceutical firms and clinical labs. Making sure a shorter TAT is achieved has gained importance as a result of the increased interest in microplate readers, automated liquid handling, and robots. On the other hand, the epidemic has led to lower spending on automation and technology, as well as lower revenues and margins for hospitals and health systems. This has an effect on the future market for modular laboratory automation.
The automated liquid handlers segment is expected to be the largest during the anticipated period. Laboratories that work with chemicals and biochemistry frequently employ liquid handlers. In laboratories, automated liquid handling robots assist with dispensing samples and other liquids. Automated liquid handlers reduce cycle times and increase precision. Additionally, liquid handlers can work with a variety of volumes, down to nanolitres, demonstrating their value in dispensing operations.
The clinical diagnostics segment is expected to witness lucrative growth during the forecast period. The ability of modular laboratory automation to optimise laboratory workflows, increase productivity, increase accuracy, and decrease the possibility of human error has led to its widespread use in clinical diagnostics. Additionally, modular automation can be used to automate different immunoassays and clinical chemistry tests, enabling laboratories to process a large number of tests quickly and with little user involvement.
Due to widespread adoption of cutting-edge technologies across all end-user segments, North America is anticipated to dominate the modular laboratory automation market. The market is predicted to be driven by investments in cutting-edge genomics, proteomics, and epigenetics research, a rise in the focus on environmental concerns, and the concentration of some of the biggest pharmaceutical and biotechnology companies in the world as well as academic institutions in the region.
The demand for lab automation solutions is expected to rise in the Asia-Pacific region, primarily as a result of the region's explosive growth in the pharmaceutical industry. The continuation of demographic and economic trends, new healthcare reforms, and the policies outlined in the government's five-year plan are all anticipated to fuel market expansion. Vendors of lab automation solutions now have new opportunities to increase their footprint thanks to the rapidly expanding market.
Some of the key players profiled in the Modular Laboratory Automation Market include: Agilent Technologies, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Honeywell International Inc., Hudson Robotics, Inc., PerkinElmer, Inc., QIAGEN N.V., Shimadzu Scientific Instruments, Siemens Healthineers, Synchron Lab Automation, Tecan Group Ltd. And Thermo Fisher Scientific, Inc.
In June 2022, MegaRobo Technologies Ltd announced the completion of a USD 300 million Series C fundraising round. MegaRobo would use the funds to continue its R&D investments, capacity growth, and global expansion. MegaRobo has offered the life sciences industry a comprehensive set of automation solutions. Ranging from benchtop workflow automation for simple workflows to a fully automated platform for complex workflows in large system journey applications, with plans to expand into the next-generation life sciences infrastructure system for R&D and AI drug development.
In May 2022, Global life science innovators MGI Tech Co. Ltd (MGI) and King Abdullah International Medical Research Center (KAIMRC) signed a Memorandum of Understanding (MOU) to form a strategic collaboration in the domains of genomic science and biotechnology. The MOU anticipates establishing a high-throughput sequencing center in KAIMRC, which may accommodate MGI's technology platforms, including DNBSEQ sequencing, laboratory automation, and bioinformatics products. Driven by MGI's proprietary DNBSEQ technology, the partnership will employ MGI's platform to improve genome sequencing and data quality across a wide range of applications.